Katherine M. Edwards

Katherine M. Edwards

Auto-generated profile, based on publicly available information

Katherine M. Edwards

Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in International Journal of Obstetric Anesthesia
Verified
Journal Article
Closed access
BMB. Marroquin
B. Marroquin
CFChangyong Feng
Changyong Feng
ABA. Balofsky
A. Balofsky
KEK. Edwards
K. Edwards
AIA. Iqbal
A. Iqbal
RWR. Wissler
R. Wissler

1 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LCLily A. Cisco
Lily A. Cisco
MSMatthew T. Sipple
Matthew T. Sipple
KEKatherine M. Edwards
Katherine M. Edwards
CTCharles A. Thornton
Charles A. Thornton
JLJohn D. Lueck
John D. Lueck
Myotonic dystrophy type 1 (DM1) involves misregulated alternative splicing for specific genes. We used exon or nucleotide deletion to mimic altered splicing of genes central to muscle excitation-contraction coupling processes in mice. Mice with forced-skipping of exon 29 in Ca V 1.1 calcium channel combined with loss of ClC-1 chloride channel function showed a markedly reduced lifespan, whereas other combinations of splicing mimics did not affect survival. The Ca 2+ /Cl - bi-channelopathy mice exhibited myotonia, weakness, and impairment of mobility and respiration. Chronic administration of the calcium channel blocker verapamil rescued survival and improved force generation, myotonia, and respiratory function. These results suggest that Ca 2+ /Cl - bi-channelopathy contributes to muscle impairment in DM1 and is potentially mitigated by common clinically available calcium channel blockers. Summary: Repurposing of a calcium channel blocker extends life and mitigates muscle and respiratory dysfunction in a myotonic dystrophy type 1 Ca 2+ /Cl - bi-channelopathy mouse model.

9 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
WKWooree Ko
Wooree Ko
JPJoseph Porter
Joseph Porter
MSMatthew T. Sipple
Matthew T. Sipple
KEKatherine M. Edwards
Katherine M. Edwards
JLJohn D. Lueck
John D. Lueck
Nonsense mutations or premature termination codons (PTCs) comprise ∼11% of all genetic lesions, which result in over 7,000 distinct genetic diseases. Due to their outsized impact on human health, considerable effort has been made to find therapies for nonsense-associated diseases. Suppressor tRNAs have long been identified as a possible therapeutic for nonsense-associated diseases, however their ability to inhibit nonsense-mediated mRNA decay (NMD) and support significant protein translation from endogenous transcripts has not been determined in mammalian cells. Here we investigated the ability of anticodon edited (ACE)-tRNAs to suppress cystic fibrosis (CF) causing PTCs in the cystic fibrosis transmembrane regulator ( CFTR ) gene in gene-edited immortalized human bronchial epithelial (16HBEge) cells. Delivery of ACE-tRNAs to 16HBEge cells harboring three common CF mutations G542X-, R1162X- and W1282X-CFTR PTCs significantly inhibited NMD and rescued endogenous mRNA expression. Furthermore, delivery of our highly active leucine encoding ACE-tRNA resulted in rescue of W1282X-CFTR channel function to levels that significantly exceed the necessary CFTR channel function for therapeutic relevance. This study establishes the ACE-tRNA approach as a potential stand-alone therapeutic for nonsense-associated diseases due to its ability to rescue both mRNA and full-length protein expression from PTC containing endogenous genes. One Sentence Summary: Suppression of endogenous CFTR nonsense mutations by anticodon engineered tRNAs significantly increases mRNA expression and channel function.